Feed / ABT

Abbott Laboratories

ABT

Healthcare · 97.55 -3.4% today

Isolated · not yet confirmedMarket checked 1 Oct, 15:00 GMT-4

Market read

No connected market move is active around Abbott Laboratories.

No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 26 directly disclosed connections are confirming.

Company-3.4% todayVolume comparison unavailable
Market groupNo active group readNo durable group available
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Rapid and Molecular Diagnostics sales decreased 8.8% (ex-FX) in 1H2026, attributed to lower demand for respiratory virus tests from a weaker respiratory virus season.

Invalidation: The isolated read changes if ABT's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Devices

No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 26 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Rapid and Molecular Diagnostics sales decreased 8.8% (ex-FX) in 1H2026, attributed to lower demand for respiratory virus tests from a weaker respiratory virus season.

Company research

Understand the business, not just the ticker

As of Oct 1, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations615
Usable filing statements104
Verified relationships9
Evidence supporting the case
  • Latest annual revenue changed +5.7% year over year.
  • Operating margin changed +1.9 percentage points in the latest annual period.
  • Operating cash flow covered net income at 1.47x in the latest annual period.
  • Foreign exchange has repeated favorable evidence across 5 filings.
Evidence challenging the case
  • Net margin changed -17.2 percentage points in the latest annual period.
  • Demand and volume has repeated adverse evidence across 5 filings.
  • Capital investment and capacity has repeated adverse evidence across 4 filings.
Questions before a position
  • P/E is 22% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 30, 2026

98.83
6m-3.7%12m-25.8%24m-12.3%
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$43.1B+24.5%$3.94+0.2%
2022-12-31$43.7B+1.3%$3.91-1.4%
2023-12-31$40.1B-8.1%$3.26-0.9%
2024-12-31$42.0B+4.6%$7.64-0.1%
2025-12-31$44.3B+5.7%$3.72+0.0%

What management says matters

Persistent and emerging business drivers

Demand and volumemixed · 5 filings
“In Rapid and Molecular Diagnostics, sales decreased 8.8 percent in the first six months of 2026, excluding the impact of foreign exchange, primarily reflecting lower demand for respiratory virus tests due to a weaker respiratory virus season compared to the p…”
10-Q · Jul 28, 2026 ↗
Foreign exchangemixed · 5 filings
“Selling, general, and administrative (SG&A) expenses increased $934 million to $4.0 billion in the second quarter, or 30.3 percent, and increased $1.6 billion to $7.8 billion, or 26.2 percent, in the first six months of 2026, primarily due to the addition of…”
10-Q · Jul 28, 2026 ↗
Capital investment and capacitynegative · 4 filings
“Liquidity and Capital Resources The decrease in cash and cash equivalents from $8.5 billion at December 31, 2025, to $5.1 billion at June 30, 2026, primarily reflects the use of cash to fund the cash portion of the acquisition of Exact Sciences and repay the…”
10-Q · Jul 28, 2026 ↗
Credit and interest ratesmixed · 4 filings
“In the second quarter and the first six months of 2026, interest expense increased primarily due to interest on debt incurred related to the acquisition of Exact Sciences, partially offset by the benefit of prior year debt repayments and interest income earne…”
10-Q · Jul 28, 2026 ↗

Valuation discipline

Descriptive valuation snapshot

Price/sales 3.9× · EV/sales 3.9×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

97.55-3.4% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 1 Oct, 15:00 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ABT. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for ABT. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind ABT

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

SPGIS&P Global Inc.lenderApr 29, 2026 ▾

“At March 31, 2026, Abbott’s long-term debt rating was A+ by S&P Global Ratings and Aa3 by Moody’s Investors Service.”

Depended on by

BBNXBeta Bionics, Inc.partnerApr 21, 2026 ▾

“We have also partnered with Dexcom and Abbott—global leaders in popular and easy to use iCGM technology—to integrate the iLet with the Dexcom G6 and G7 iCGMs and with Abbott’s FreeStyle Libre 3 Plus Continuous Glucose Monitor (CGM) sensor.”

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 24 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ABT is currently a Follower in the organic co-movement group Unknown Theme. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for ABT; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.